New drug proves its viability in the fight against lymphoma

WASHINGTON (Reuters) – A recently approved drug has proven to be very effective in treating a type of leukemia, a large cell lymphoma, according to a recent US study.

The study, conducted by researchers at the MD Anderson Cancer Center of the University of Texas in the United States, presented its findings Monday at the annual conference on hematology, to be held from 1 to December 4 in San Diego, United States.
The team studied the effectiveness of Axi-cel, which was approved by the US Food and Drug Administration in October 2017 and by the European Commission in August 2018 for the treatment of lymphoma.
In a study of 27 patients with large cell lymphoma over 27 months, the results showed that 51% of patients who received the new drug were still alive after two years of treatment.
The researchers found that 83% of patients had achieved a reduction in cancer-related treatment called objective response, while the full response rate of treatment was 58%.
The new main treatment idea is to extract the immune cells from the patient's body and reconfigure their genes so that they only attack the tumor, then return them to the body to do the work and remove the tumor. Cancer.